Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Short-seller Citron calls Express Scripts drug price culprit

Published 12/09/2016, 07:10 AM
Updated 12/09/2016, 07:10 AM
Short-seller Citron calls Express Scripts drug price culprit

Short-seller Citron calls Express Scripts drug price culprit

By Deena Beasley

(Reuters) - Short seller Citron Research's Andrew Left has turned his sights on Express Scripts Holding Co, calling the pharmacy benefit manager (PBM) the "culprit behind pharmaceutical price gouging."

Shares of Express Scripts, the largest PBM in the United States, fell 6.7 percent to close at $70.75 on Nasdaq. Citron, which profits from bets that stock prices will fall, set a price target of $45 on the company's shares.

Express Scripts "is Philidor of the pharma industry. @therealdonaldtrump promises to fix drug pricing? Two words: EXPRESS SCRIPTS," Citron tweeted on Thursday.

President-elect Donald Trump, in a Time magazine article on Wednesday, said he would "bring down drug prices."

"We make money when our clients save money," Express Scripts said in comments emailed on Thursday. "The vast majority of rebates we negotiate go directly back to our clients."

PBMs like Express Scripts manage prescription drug plans for employers and insurers. Philidor Rx Services, now closed, was a mail order pharmacy linked to efforts by Valeant Pharmaceuticals International Inc (NYSE:VRX) to steer prescriptions to its high-priced drugs.

Left, during an interview on CNBC, said Express Scripts benefits from the "opaqueness" of drug pricing, but "by no means am I saying that this company is a fraud."

PBMs have in recent years taken an increasingly aggressive stance in price negotiations with pharmaceutical companies, in some cases limiting access to rival drugs in specific categories in return for discounts to list prices or rebates.

Shares of Express Scripts have struggled for most of this year after a major customer, health insurer Anthem Inc, sued the company over drug rebates.

Citron sparked the investigation into the relationship between Valeant and now-shuttered Philidor with a report issued in October 2015.

A former Valeant executive and the former CEO of Philidor were arrested last month on charges that they engaged in a multimillion-dollar fraud and kickback scheme.

Shares of drugstore operator CVS Health Corp (NYSE:CVS), which has a PBM unit, fell 3 percent to close at $78.11 on the New York Stock Exchange.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.